Suven Pharmaceuticals Share Price

    NSE
    1019.3
    +23.35 (2.38%)
    SUVENPHAR • 11 Jul, 2025 | 01:24 PM
    BUY

    1Y Annualised Return

    16.62%

    3Y Annualised Return

    30.79%

    5Y Annualised Return

    29.87%

    The current prices are delayed, login or Open Demat Account for live prices.

    Suven Pharmaceuticals Stock Performance

    1W Return-1.93
    1Y Return19.02
    Today's Low988
    Prev. Close995.95
    Mkt Cap (Cr.)38,101.77
    1M Return1.42
    3Y Return129.10
    52-Week High1360
    Open1,000.75
    PE Ratio140.21
    6M Return-4.28
    Today's High1029.15
    52-Week Low795.65
    Face Value1

    Suven Pharmaceuticals Company background

    Founded in: 2018
    Managing director: Venkatanaga Kali Vara Prasad Raju Vetukuri
    Suven Pharmaceuticals Limited (SPL) is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors. The Companys comprehensive services encompass Custom Synthesis, Process RD,ScaleUp, and Contract Manufacturing of intermediates, APIs, and formulations. Suven Pharmaceuticals Limited was incorporated on 6 November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. The Company has established core competencies in cyanation and heterocyclic chemistry, covering pyrimidines, quinolones, thiazoles, and imidazoles.The Company is a CDMO that supports global life sciences industry and fine chemical majors in their NCE development endeavors. Its services include custom synthesis, process RD, scaleup and contract manufacturing of intermediates, APIs and formulations. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry.During the year 201920, Suven Life Sciences Ltd. (SLSL) has transferred the CRAMS Business Undertaking Division to the Company through the Scheme of Arrangement (Demerger) approved by the Honble NCLT, Hyderabad Bench now integrated with Contract Development and Manufacturing Operations (CDMO) business model of the Company. In terms of the sanctioned Scheme, the Company issued and allotted 1 (One) fully paid up equity share of face value of Re 1/ (Rupee One only) each of SPL for every 1 (One) fully paid up equity share of face value of Re 1/ (Rupee One only) each held by each shareholder in the Demerged Company (SLSL) as on the Record Date (i.e., 22nd January, 2020), thereby resulted in a mirror shareholding of SLSL in the Company. The equity shares of the Company were listed to trade w.e.f. 09th March, 2020.The Board of Directors in its meeting held on August 17, 2020 considered, approved and recommended an issue of bonus shares in the proportion of (1:1) one new equity share of the Company of Re 1 each for every one existing equity share of the Company of Re 1 each.The company has a massive Rs 320crore capex plan. Suven has invested Rs 120 crore in 201920. The balance is to be invested in 202021.During the year 201920, the Company invested USD35 million in Rising Pharma Holdings, Inc., USA through its wholly owned subsidiary, Suven Pharma, Inc., USA. Suven Pharma, Inc., in USA was originally formed by Suven Life Sciences Ltd while pursuing various business opportunities in CRAMS business undertaking during the demerger transition period now integrated with CDMO business of the Company, as per the decisions taken by the Board of the Company and of the Demerged Company i.e., Suven Life Sciences Ltd, in accordance with the enabling provisions of Scheme of Arrangement as sanctioned by Honble NCLT Hyderabad Bench. As a result, Suven Pharma, Inc., in USA has become wholly owned subsidiary of the company during the FY 20192020.As on 31 March 2020,the company has one subsidiary and one associate company under its roof.The company filed 11 ANDAs as on March 31, 2020 and three of those secured the green light from the regulator.The Board has allotted the Bonus shares at 1:1 ratio in its Board Meeting held on 29 September 2020. Accordingly the number of shares increased from 12,72,82,478 to 25,45,64,956..In 2022, the Company filed 17 ANDAs of which 9 had received approvals and 8 products were launched up to March, 2022.During year 2022, Company acquired 100% stake in Casper Pharma Private Limited, a Hyderabad based SEZ unit and Casper Pharma became a Wholly Owned Subsidiary of the company.

    As of 11 Jul, 2025, Suven Pharmaceuticals share price is ₹. The stock opened at ₹ and had closed at ₹ the previous day. During today’s trading session, Suven Pharmaceuticals share price moved between ₹988.00 and ₹1,029.15, with an average price for the day of ₹1008.58. Over the last 52 weeks, the stock has recorded a low of ₹795.65 and a high of ₹1,360.00. In terms of performance, Suven Pharmaceuticals share price has declined by NaN% over the past six months and has increased by 16.62% over the last year.

    Read More
    Suven Pharmaceuticals SIP Return Calculator

    Over the past

    1 year
    3 years
    5 years
    Total Investment of ₹65,00,000
    Would have become ₹70,73,426 (+8.82%)
    Daily SIP of 25,000 would have become 70,73,426 in 1 year with a gain of 5,73,426 (+8.82%)
    View details of Market Depth

    Suven Pharmaceuticals Fundamental

    Market Cap (in crs)

    38,101.77

    Face Value

    1

    Turnover (in lacs)

    2,466.91

    Suven Pharmaceuticals Result Highlights

    • Suven Pharmaceuticals Ltd reported a 18.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 37.9%.

    • Its expenses for the quarter were up by 23.7% QoQ and 26.3% YoY.

    • The net profit increased 1.6% QoQ and increased 78.2% YoY.

    • The earnings per share (EPS) of Suven Pharmaceuticals Ltd stood at 3.2 during Q3FY25.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Suven Pharmaceuticals Share Price FAQs

    Suven Pharmaceuticals share price is ₹1019.3 in NSE and ₹1019.35 in BSE as on 11/7/2025.

    Suven Pharmaceuticals share price in the past 1-year return was 19.02. The Suven Pharmaceuticals share hit a 1-year low of Rs. 795.65 and a 1-year high of Rs. 1360.

    The market cap of Suven Pharmaceuticals is Rs. 38101.77 Cr. as of 11/7/2025.

    The PE ratios of Suven Pharmaceuticals is 140.21 as of 11/7/2025.

    The PB ratios of Suven Pharmaceuticals is 16.35 as of 11/7/2025

    You can easily buy Suven Pharmaceuticals shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Suven Pharmaceuticals share price is ₹1360 and ₹795.65 as of 11/7/2025.

    Please be aware that Suven Pharmaceuticals stock prices are subject to continuous fluctuations due to various factors.

    Popular Stocks
    65.60
    -0.37 (-0.56%)
    136.03
    -1.10 (-0.80%)
    684.80
    -10.80 (-1.55%)
    2,571.50
    -9.50 (-0.37%)
    161.10
    -8.54 (-5.03%)
    383.85
    -0.85 (-0.22%)
    159.55
    -1.11 (-0.69%)
    263.65
    +0.80 (+0.30%)
    411.40
    -2.10 (-0.51%)
    399.20
    -0.70 (-0.18%)
    Top Gainers
    2,518.70
    +110.30 (+4.58%)
    1,830.00
    +19.80 (+1.09%)
    264.30
    +1.45 (+0.55%)
    1,671.30
    +8.80 (+0.53%)
    1,170.00
    +5.70 (+0.49%)
    Top Losers
    3,273.00
    -109.00 (-3.22%)
    7,176.50
    -182.50 (-2.48%)
    258.95
    -6.10 (-2.30%)
    8,095.50
    -189.50 (-2.29%)
    3,090.90
    -71.50 (-2.26%)
    Open Demat Account
    +91 -

    Open Demat Account
    +91 -